Incyte

CompanyUnited StatesFounded 2001

RORWikidata

Incyte develops 13 assets, the furthest approved (baricitinib in Active Rheumatoid Arthritis). Mostly small molecule and antibody acting on PDCD1, JAK2 and JAK1; based in the United States, founded in 2001.

13
Assets
Furthest stage
Approved
181
Trials
38
Signals

Pipeline

13
  • baricitinib

    Selective JAK1 and JAK2 inhibitor that reduces inflammatory signaling pathways.

    Approved, Small molecule, JAK2, JAK1, Active Rheumatoid Arthritis, rheumatoid arthritis, Partner

  • Niktimvo

    Blocks colony stimulating factor-1 receptor signaling to reduce pathogenic macrophage activity in chronic graft-versus-host disease.

    Approved, Antibody, CSF1R, chronic graft versus host disease, idiopathic pulmonary fibrosis (Phase 2)

  • ponatinib

    Inhibits BCR-ABL kinase, including the T315I resistance mutant, to suppress leukemic cell growth.

    Approved, Small molecule, BCR, ABL1, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, chronic myeloid leukemia

10 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms9
  • Trials332
  • Deals8
  • People18
  • Signals20
  • Similar companies6

Papers

Intelligence